drugset / Trial / NCT07804966
Sac-TMT in Vaginal and Vulvar Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The ARCANA trial (LACOG 1724) is a single-arm, non-randomized, multi-center, parallel, two-cohort Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT, MK-2870) as a second-line or subsequent treatment in patients with advanced or metastatic vaginal and vulvar squamous cell carcinomas. Given the rarity of these cancers and the lack of standard second-line therapies, this study explores sac-TMT, a novel TROP-2-directed antibody-drug conjugate (ADC). TROP-2 is highly expressed in both vulvar and vaginal squamous cell carcinomas, making it a promising therapeutic target.
Timeline
- Start
- 2027-01
- Primary completion
- 2030-03
- Completion
- 2032-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |